Key result
YM-16151-4, a combined calcium entry and beta 1-adrenoceptor blocker, was fully effective in various experimental angina models in contrast to nifedipine and propranolol.
Why the study?
Does YM-16151-4 improve antianginal parameters in experimental angina models compared to nifedipine and propranolol?
Does YM-16151-4 improve antianginal parameters in experimental angina models compared to nifedipine and propranolol?
YM-16151-4 demonstrates broad antianginal efficacy in preclinical models through combined calcium channel and beta-1 receptor blockade.
No takes yet. Share an insight, caveat, or question.
Supports dual calcium-beta blockade in experimental angina; hypothesis-generating for clinical translation and should not change practice.
Uchida et al. (1993) studied Experimental angina. YM-16151-4 vs. Nifedipine and propranolol was evaluated on Antianginal effects (coronary blood flow, MVO2, ST-segment changes). YM-16151-4, a combined calcium entry and beta 1-adrenoceptor blocker, was fully effective in various experimental angina models in contrast to nifedipine and propranolol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: